The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer
Open Access
- 18 July 2022
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 12 (7) , 1737
Abstract
The morbidity and mortality caused by endometrial cancer (EC) is still rising worldwide. In recent years, a new system of tumor stratification has been proposed based on POLE-mutational status, TP53, and microsatellite stability status. The aim of the study was to analyze a vast panel on the genes potentially involved in the genesis of endometrial cancer in the Polish population. One hundred and three white female patients with confirmed endometrial cancer were enrolled on the study. We performed sequencing using the Hot Spot Illumina panel and microsatellite stability with immunohistochemistry. We confirmed a key role of the TP53 mutation in progress to high-grade EC and parallelly some role of FGFR2 mutation. Moreover, our data present a vast landscape of mutations in EC and their polymorphism. We reported the meaning of FGFR2 mutation and TP53 (high copy number) in high-grade ECs. Our observation in MSI contribution is comparable with other studies. Finally, we see a strong need for the implementation of the TCGA classification.Keywords
Funding Information
- “Regional Initiative of Excellence” in the years 2019–2022 (024/RID/2018/19)
This publication has 28 references indexed in Scilit:
- New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical careGynecologic Oncology Research and Practice, 2016
- Endometrial cancerThe Lancet, 2016
- Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysisWorld Journal of Surgical Oncology, 2015
- Classification of endometrial carcinoma: more than two typesThe Lancet Oncology, 2014
- HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic ChallengesArchives of Pathology & Laboratory Medicine, 2014
- Cancer-Associated Fibroblasts Promote Proliferation of Endometrial Cancer CellsPLOS ONE, 2013
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- [Disturbance of gene expression in endometrial cancer as therapy aim].2011
- Description of a Novel System for Grading of Endometrial Carcinoma and Comparison With Existing Grading SystemsAmerican Journal of Surgical Pathology, 2005
- Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinomaCancer, 2004